Loading
A phase 3 trial of Datopotamab deruxtecan, Durvalumab, Carboplatin, Pembrolizumab, Cisplatin and Pemetrexed in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations is a phase 3 interventional study registered as NCT05687266 by AstraZeneca, with 1350 participants enrolled, started 2022-12-29 and due to reach its primary completion in 2027-11-01. Interventions recorded: Datopotamab deruxtecan, Durvalumab, Carboplatin, Pembrolizumab, Cisplatin and Pemetrexed.
Shares Durvalumab, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca, Platinum agents and the tag pipeline.
Shares Pemetrexed, Durvalumab, AstraZeneca, Cisplatin and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Durvalumab, AstraZeneca, Cisplatin and the tag pipeline.
Shares Datopotamab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Topoisomerase-I inhibitors (and ADC payloads), Platinum agents, Carboplatin, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.